These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 28923441)

  • 1. CAR T cell immunotherapy in hematology and beyond.
    Rossig C
    Clin Immunol; 2018 Jan; 186():54-58. PubMed ID: 28923441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontiers in CAR-T cell therapy for autoimmune diseases.
    Li YR; Lyu Z; Chen Y; Fang Y; Yang L
    Trends Pharmacol Sci; 2024 Sep; 45(9):839-857. PubMed ID: 39147651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T cells for treating autoimmune diseases.
    Blache U; Tretbar S; Koehl U; Mougiakakos D; Fricke S
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting natural killer group 2D receptors for CAR T-cell therapy.
    Demoulin B; Cook WJ; Murad J; Graber DJ; Sentman ML; Lonez C; Gilham DE; Sentman CL; Agaugue S
    Future Oncol; 2017 Aug; 13(18):1593-1605. PubMed ID: 28613086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-cell therapy in autoimmune diseases.
    Schett G; Mackensen A; Mougiakakos D
    Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases.
    Su M; Zhao C; Luo S
    Autoimmun Rev; 2022 Jan; 21(1):102931. PubMed ID: 34481941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; NÓ§lle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular Immunotherapy in B-Cell Malignancy.
    Schwarzbich MA; Witzens-Harig M
    Oncol Res Treat; 2017; 40(11):674-681. PubMed ID: 29065420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
    Maus MV; Levine BL
    Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
    MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
    Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
    Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intelligent cell-based therapies for cancer and autoimmune disorders.
    Chen R; Jing J; Siwko S; Huang Y; Zhou Y
    Curr Opin Biotechnol; 2020 Dec; 66():207-216. PubMed ID: 32956902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.